{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:38:03Z","timestamp":1792586283859,"version":"4.5.0"},"reference-count":48,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100018948","name":"Saudi Arabian Cultural Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"publisher","award":["KKL501"],"award-info":[{"award-number":["KKL501"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016131","name":"Howat Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X008169\/1"],"award-info":[{"award-number":["MR\/X008169\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Molecular Oncology"],"abstract":"<jats:p>Signals emanating from the B cell receptor (BCR) are vital for driving cell survival and proliferation in chronic lymphocytic leukaemia (CLL). BCR\u2010mediated signals in CLL cells promote nuclear exclusion and inactivation of the transcription factor forkhead box protein O1 (FOXO1) and transient upregulation of FOXO1 expression. To investigate the mechanisms that regulate FOXO1 inactivation, we focused on the role of deubiquitinase (DUB) family proteins. Stratifying expression of individual DUB proteins, we established that ubiquitin\u2010specific protease 7 (USP7), USP8, USP9x, USP10 and USP14 are significantly upregulated compared to healthy B\u00a0cells. USP7 interacts with FOXO1 in primary CLL cells, suggesting that modulation of USP7 activity may impact FOXO1 function. Using selective USP7 inhibitors, P5091 and HBX19818, or USP7 knockdown, combined with ibrutinib, we demonstrated enhanced FOXO1 nuclear localisation over ibrutinib alone and increased FOXO1 activity, leading to modulation of selected FOXO target genes. This resulted in reduced CLL cell viability and enhanced cell cycle arrest in MEC1 cells, largely reversed by FOXO1 knockdown. These findings suggest that dual targeting of BCR signalling and USP7 activity can harness FOXO1\u2010mediated anti\u2010tumour activity and may represent a novel therapeutic approach for CLL treatment.<\/jats:p>","DOI":"10.1002\/1878-0261.70350","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:38:28Z","timestamp":1792582708000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>USP7<\/scp>\n                    inhibits\n                    <scp>FOXO1<\/scp>\n                    activity in chronic lymphocytic leukaemia cells enhancing cell survival"],"prefix":"10.1002","author":[{"given":"Hassan N.B.","family":"Almuhanna","sequence":"first","affiliation":[{"name":"School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences University of Glasgow  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Hay","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences University of Glasgow  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Moles","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences University of Glasgow  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Clarke","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences University of Glasgow  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cassels","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences University of Glasgow  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Sefcick","sequence":"additional","affiliation":[{"name":"NHS Greater Glasgow &amp; Clyde Royal Alexandra Hospital  Paisley UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"McCaig","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences University of Glasgow  UK"},{"name":"NHS Greater Glasgow &amp; Clyde Queen Elizabeth University Hospital  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather G.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences University of Glasgow  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-475X","authenticated-orcid":false,"given":"Alison M.","family":"Michie","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences University of Glasgow  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"3","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek M","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"e_1_2_11_3_1","first-page":"1","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps TJ","year":"2017","journal-title":"Natl Rev"},{"issue":"10453","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic lymphocytic leukemia","volume":"404","author":"Jain N","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","article-title":"Microenvironment interactions and B\u2010cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment","volume":"1863","author":"Ten Hacken E","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41375-018-0303-x","article-title":"The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia","volume":"33","author":"Ten Hacken E","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8\u2010year follow\u2010up from RESONATE\u20102: first\u2010line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr PM","year":"2022","journal-title":"Blood Adv"},{"issue":"16","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open\u2010label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman JP","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tig.2011.03.003","article-title":"Forkhead transcription factors: key players in health and disease","volume":"27","author":"Benayoun BA","year":"2011","journal-title":"Trends Genet"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.ctdb.2017.10.006","article-title":"Regulation of FOXO factors in mammalian cells","volume":"127","author":"Brown AK","year":"2018","journal-title":"Curr Top Dev Biol"},{"issue":"11","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbamcr.2011.01.007","article-title":"Regulation of FOXO protein stability via ubiquitination and proteasome degradation","volume":"1813","author":"Huang H","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrm1700","article-title":"Ubiquitin and ubiquitin\u2010like proteins as multifunctional signals","volume":"6","author":"Welchman RL","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nrm2190","article-title":"Stressing the role of FoxO proteins in lifespan and disease","volume":"8","author":"Horst A","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/ars.2010.3405","article-title":"Forkhead homeobox type O transcription factors in the responses to oxidative stress","volume":"14","author":"Storz P","year":"2011","journal-title":"Antioxid Redox Signal"},{"issue":"20","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"11285","DOI":"10.1073\/pnas.1934283100","article-title":"Insulin\u2010induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation","volume":"100","author":"Matsuzaki H","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","article-title":"Deubiquitinases in cancer","volume":"23","author":"Dewson G","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-18-2036","article-title":"AKT\/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B\u2010cell receptor\u2010mediated survival","volume":"25","author":"Cosimo E","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-06-654111","article-title":"FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal\u2010dependent diffuse large B\u2010cell lymphomas","volume":"127","author":"Szydlowski M","year":"2016","journal-title":"Blood"},{"issue":"3","key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-09-3071","article-title":"Optimal B\u2010cell proliferation required phosphoinositide 3\u2010kinase\u2010dependent inactivation of FOXO transcription factors","volume":"104","author":"Yusuf I","year":"2004","journal-title":"Blood"},{"issue":"4","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1073\/pnas.1017729108","article-title":"14\u20103\u20103sigma regulated B\u2010cell homeostasis through stabilization of FOXO1","volume":"108","author":"Su YW","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1073\/pnas.0406789102","article-title":"Skp2 inhibits FOXO1 in tumor suppression through ubiquitin\u2010mediated degradation","volume":"102","author":"Huang H","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/ncb1469","article-title":"FOXO4 transcriptional activity is regulated by monoubiquitination and USP7\/HAUSP","volume":"8","author":"Van der Horst A","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"22","key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"35508","DOI":"10.18632\/oncotarget.16348","article-title":"Therapeutic inhibition of USP7\u2010PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated\/deleted clones","volume":"8","author":"Carr\u00e0 G","year":"2017","journal-title":"Oncotarget"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117075","article-title":"Artesunate attenuates osteoarthritis in mice by promoting MTA1 transcription through a USP7\/FoxO1 axis","volume":"491","author":"Zhao C","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/me.2013-1420","article-title":"USP7 attenuates hepatic gluconeogenesis through modulation of FoxO1 gene promoter occupancy","volume":"28","author":"Hall JA","year":"2014","journal-title":"Mol Endocrinol"},{"key":"e_1_2_11_26_1","article-title":"Subcellular fractionation of primary chronic lymphocytic leukaemia cells to monitor nuclear\/cytoplasmic protein trafficking","volume":"152","author":"Hay J","year":"2019","journal-title":"J Vis Exp"},{"issue":"2","key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: two new cell lines derived from B\u2010chronic lymphocytic leukemia in prolymphocytoid transformation","volume":"23","author":"Stacchini A","year":"1999","journal-title":"Leuk Res"},{"issue":"9","key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1038\/s41375-019-0451-7","article-title":"Human MLL\/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL\u2013USP2 fusions","volume":"33","author":"Meyer C","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","author":"Tian Z","year":"2014","journal-title":"Blood"},{"issue":"4","key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41401-020-0455-x","article-title":"Wu\u20105, a novel USP10 inhibitor, enhances crenolanib\u2010induced FLT3\u2010ITD\u2010positive AML cell death via inhibiting FLT3 and AMPK pathways","volume":"42","author":"Yu M","year":"2021","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.7150\/thno.36503","article-title":"Deubiquitinase USP28 inhibits ubiquitin ligase KLHL2\u2010mediated uridine\u2010cytidine kinase 1 degradation and confers sensitivity to 5\u2032\u2010azacytidine\u2010resistant human leukemia cells","volume":"10","author":"Zhang H","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2016-12-758219","article-title":"USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM\/p53 functional status","volume":"130","author":"Agathanggelou A","year":"2017","journal-title":"Blood"},{"issue":"7","key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1074\/jbc.RA119.010724","article-title":"The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival","volume":"295","author":"He Y","year":"2020","journal-title":"J Biol Chem"},{"issue":"6","key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1172\/JCI85747","article-title":"Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis","volume":"126","author":"Wang Q","year":"2016","journal-title":"J Clin Invest"},{"issue":"10","key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1172\/JCI120518","article-title":"Ubiquitin\u2010specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis","volume":"128","author":"Su D","year":"2018","journal-title":"J Clin Invest"},{"issue":"47","key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"77096","DOI":"10.18632\/oncotarget.12801","article-title":"CDDO\u2010me reveals USP7 as a novel target in ovarian cancer cells","volume":"7","author":"Qin D","year":"2016","journal-title":"Oncotarget"},{"issue":"7214","key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nature07290","article-title":"The deubiquitinylation and localization of PTEN are regulated by a HAUSP\u2013PML network","volume":"455","author":"Song MS","year":"2008","journal-title":"Nature"},{"key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature737","article-title":"Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization","volume":"416","author":"Li M","year":"2002","journal-title":"Nature"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nsmb1067","article-title":"Molecular recognition of p53 and MDM2 by USP7\/HAUSP","volume":"13","author":"Sheng Y","year":"2006","journal-title":"Nat Struct Mol Biol"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1756-8722-6-83","article-title":"Detection of TP53 dysfunction in chronic lemphocytic leukemia by a in vitro functaionl assay based on TP53 activation by the non\u2010toxic drug Nutlin: a proposal for clinical application","volume":"6","author":"Pozzo F","year":"2013","journal-title":"J Hematol Oncol"},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.650165","article-title":"Proteome analysis of USP7 substrates revealed its role in melanoma through PI3K\/Akt\/FOXO and AMPK pathways","volume":"11","author":"Gao L","year":"2021","journal-title":"Front Oncol"},{"key":"e_1_2_11_42_1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K\u2010\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold A","year":"2019","journal-title":"Blood"},{"key":"e_1_2_11_43_1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173770","article-title":"FoxO1\/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia","volume":"134","author":"Ondrisova L","year":"2024","journal-title":"J Clin Invest"},{"issue":"13","key":"e_1_2_11_44_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108564","article-title":"mTORC2 assembly is regulated by USP9x\u2010mediated deubiqutiniation of RICTOR","volume":"33","author":"Wrobel L","year":"2020","journal-title":"Cell Rep"},{"key":"e_1_2_11_45_1","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.1005727","article-title":"Highlights in USP7 inhibitors for cancer treatment","volume":"10","author":"Oliveira RI","year":"2022","journal-title":"Front Chem"},{"issue":"7677","key":"e_1_2_11_46_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small\u2010molecule inhibitors","volume":"550","author":"Turnbull AP","year":"2017","journal-title":"Nature"},{"issue":"5","key":"e_1_2_11_47_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109693","article-title":"Ubiquitin\u2010specific protease 7 inhibitors reveal a differentiated mechanism of p53\u2010driven anti\u2010cancer activity","volume":"27","author":"Futran AS","year":"2024","journal-title":"Iscience"},{"key":"e_1_2_11_48_1","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and\/or refractory multiple myeloma","volume":"38","author":"Rowinsky EK","year":"2020","journal-title":"Invest New Drugs"},{"issue":"22","key":"e_1_2_11_49_1","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jmb.2017.05.025","article-title":"Generation and validation of intracellular ubiquitin variant inhibitors for USP7 and USP10","volume":"429","author":"Zhang W","year":"2017","journal-title":"J Mol Biol"}],"container-title":["Molecular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1878-0261.70350","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:38:35Z","timestamp":1792582715000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1878-0261.70350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":48,"alternative-id":["10.1002\/1878-0261.70350"],"URL":"https:\/\/doi.org\/10.1002\/1878-0261.70350","archive":["Portico"],"relation":{},"ISSN":["1574-7891","1878-0261"],"issn-type":[{"value":"1574-7891","type":"print"},{"value":"1878-0261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"2026-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1878-0261.70350"}}